HRP20191489T1 - Kombinirani sastav - Google Patents

Kombinirani sastav Download PDF

Info

Publication number
HRP20191489T1
HRP20191489T1 HRP20191489T HRP20191489T1 HR P20191489 T1 HRP20191489 T1 HR P20191489T1 HR P20191489 T HRP20191489 T HR P20191489T HR P20191489 T1 HRP20191489 T1 HR P20191489T1
Authority
HR
Croatia
Prior art keywords
composition
combination
paracetamol
ibuprofen
use according
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Hartley Campbell Atkinson
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191489(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of HRP20191489T1 publication Critical patent/HRP20191489T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
HRP20191489 2010-11-04 2011-10-26 Kombinirani sastav HRP20191489T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition
EP11838295.1A EP2635269B1 (en) 2010-11-04 2011-10-26 A combination composition

Publications (1)

Publication Number Publication Date
HRP20191489T1 true HRP20191489T1 (hr) 2019-11-15

Family

ID=46024668

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191489 HRP20191489T1 (hr) 2010-11-04 2011-10-26 Kombinirani sastav

Country Status (28)

Country Link
US (6) US20130225685A1 (enExample)
EP (1) EP2635269B1 (enExample)
JP (2) JP2013541583A (enExample)
KR (1) KR101900520B1 (enExample)
CN (2) CN107519159A (enExample)
AU (1) AU2011324137B2 (enExample)
BR (1) BR112013010829B8 (enExample)
CA (1) CA2814057C (enExample)
CL (1) CL2013001250A1 (enExample)
CO (1) CO6771406A2 (enExample)
CY (1) CY1123398T1 (enExample)
DK (1) DK2635269T3 (enExample)
ES (1) ES2742373T3 (enExample)
HR (1) HRP20191489T1 (enExample)
HU (1) HUE045442T2 (enExample)
LT (1) LT2635269T (enExample)
MX (2) MX367209B (enExample)
MY (1) MY160572A (enExample)
NZ (1) NZ609727A (enExample)
PH (2) PH12013500689A1 (enExample)
PL (1) PL2635269T3 (enExample)
PT (1) PT2635269T (enExample)
RS (1) RS59258B1 (enExample)
RU (2) RU2707089C2 (enExample)
SG (1) SG189319A1 (enExample)
SI (1) SI2635269T1 (enExample)
SM (1) SMT201900481T1 (enExample)
WO (1) WO2012060719A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742373T3 (es) 2010-11-04 2020-02-14 Aft Pharmaceuticals Ltd Una composición de combinación
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
EP4480495A3 (en) * 2017-07-10 2025-06-18 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση
IL324832A (en) 2023-06-02 2026-01-01 Ioulia Tseti Pharmaceutical composition comprising ibuprofen
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
JP5185488B2 (ja) * 2001-11-02 2013-04-17 カンバーランド ファーマシューティカルズ,インコーポレーテッド 2−(4−イソブチルフェニル)プロピオン酸の医薬組成物
KR101113005B1 (ko) * 2003-03-21 2012-02-24 맥네일-피피씨, 인코포레이티드 비-스테로이드계 항염증성 약물 투여법
BRPI0512756A (pt) * 2004-07-07 2008-04-08 Aft Pharmaceuticals Ltd composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
ES2651444T3 (es) * 2006-10-20 2018-01-26 Johnson & Johnson Consumer Inc. Combinación de acetaminofeno con ibuprofeno para el tratamiento del dolor
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
TR201906742T4 (tr) * 2008-10-14 2019-05-21 Aft Pharmaceuticals Ltd Tıbbi bir ürün ve tedavi.
AU2010224063B2 (en) * 2009-03-12 2015-04-16 Cumberland Pharmaceuticals Inc Administration of intravenous ibuprofen
NZ604009A (en) * 2010-07-07 2015-03-27 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
ES2742373T3 (es) 2010-11-04 2020-02-14 Aft Pharmaceuticals Ltd Una composición de combinación
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛

Also Published As

Publication number Publication date
US20160235695A1 (en) 2016-08-18
LT2635269T (lt) 2019-09-10
PH12013500689A1 (en) 2013-05-27
KR101900520B1 (ko) 2018-09-19
US11896567B2 (en) 2024-02-13
PT2635269T (pt) 2019-09-04
CA2814057A1 (en) 2012-05-10
MX2013005113A (es) 2013-06-03
EP2635269B1 (en) 2019-05-22
HUE045442T2 (hu) 2019-12-30
US20250134839A1 (en) 2025-05-01
MX367209B (es) 2019-07-22
JP6353577B2 (ja) 2018-07-04
PH12021550804A1 (en) 2022-02-14
ES2742373T3 (es) 2020-02-14
SMT201900481T1 (it) 2019-11-13
BR112013010829A2 (pt) 2016-08-16
US20190029982A1 (en) 2019-01-31
RU2707089C2 (ru) 2019-11-22
AU2011324137A1 (en) 2013-05-02
US20240207210A1 (en) 2024-06-27
CY1123398T1 (el) 2021-10-29
RU2015103107A (ru) 2015-06-20
CN107519159A (zh) 2017-12-29
US11446266B2 (en) 2022-09-20
PL2635269T3 (pl) 2019-11-29
RU2013123646A (ru) 2014-12-10
BR112013010829B1 (pt) 2021-12-21
CL2013001250A1 (es) 2013-08-30
EP2635269A4 (en) 2014-09-17
RS59258B1 (sr) 2019-10-31
US20130225685A1 (en) 2013-08-29
JP2017132791A (ja) 2017-08-03
KR20140025314A (ko) 2014-03-04
AU2011324137B2 (en) 2015-05-07
CA2814057C (en) 2022-02-01
DK2635269T3 (da) 2019-08-26
NZ609727A (en) 2015-07-31
US12220392B2 (en) 2025-02-11
JP2013541583A (ja) 2013-11-14
SI2635269T1 (sl) 2019-10-30
CO6771406A2 (es) 2013-10-15
WO2012060719A1 (en) 2012-05-10
SG189319A1 (en) 2013-05-31
CN103298464A (zh) 2013-09-11
EP2635269A1 (en) 2013-09-11
US20230000805A1 (en) 2023-01-05
RU2015103107A3 (enExample) 2018-08-20
MY160572A (en) 2017-03-15
BR112013010829B8 (pt) 2022-01-04

Similar Documents

Publication Publication Date Title
CR20150232A (es) Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX355294B (es) Artículos para el cuidado personal que tienen composiciones para el cuidado personal que tienen múltiples zonas amoldables.
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
CL2013001433A1 (es) Composicion que comprende al menos una n-acetil lactosamina, al menos un oligosacarido sialilado al menos un oligosacarido fucosilado; y su uso en la prevencion de infecciones respiratorias agudas y/o para aliviar los sintomas de dichas infecciones.
CY1123398T1 (el) Συνθεση συνδυασμου
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
BR112014011067A8 (pt) proteção absorvente descartável
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
BR112015015864A2 (pt) composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica
MX390159B (es) Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada.
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
CL2014003503A1 (es) Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano.
CL2014003081A1 (es) Una composicion farmaceutica topica que comprende, en base al peso total de la composicion, 1,5-5 % en peso de terbinafina, 15-35 % en peso de urea y mas que 25 % en peso de agua; y su uso para el tratamiento topico de una infeccion fungica, preferiblemente onicomicosis.
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
CO6551731A2 (es) Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica
WO2014182789A3 (en) Radiomitigating pharmaceutical formulations
AR091186A1 (es) Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isonicotinamida
MY164112A (en) A combination composition comprising ibuprofen and paracetamol
CL2012003065A1 (es) Combinación farmacéutica que comprende ibuprofeno y l-arginina en una proporción en peso de ibuprofeno/l-arginina entre 1.6 y 5.6, con excepción del valor 1.97; composición farmacéutica sólida que contiene a dicha combinación; y su uso en el tratamiento del dolor, inflamación y/o fiebre.
WO2015004634A3 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
BR112015019387A2 (pt) alimentação mineral - através de formulação
BR112014026158A2 (pt) métodos e composições para o tratamento de infecções virais